The correlation of vitamin D with HOMA-IR and glycated hemoglobin in type 2 diabetes mellitus patients

Authors

  • Sujesh-Kumar Narayanan Department of Biochemistry, Sree Uthradom Thirunal (SUT) Academy of Medical Sciences, Trivandrum, Kerala, India
  • Renjith Gopikuttan Department of Biochemistry, Sree Uthradom Thirunal (SUT) Academy of Medical Sciences, Trivandrum, Kerala, India

DOI:

https://doi.org/10.47419/bjbabs.v3i04.153

Keywords:

HOMA-IR, HbA1c, type 2 diabetes mellitus, vitamin D

Abstract

Background and objective: Vitamin D’s primary functions are the homeostasis of calcium and bone metabolism, but it also has a significant role in the homeostasis of plasma glucose. This study sought to examine the relationship between vitamin D and glycated hemoglobin and insulin resistance in type 2 diabetes mellitus (T2DM).

Methods: A total of 150 patients with newly diagnosed T2DM participated in this case-control study. Additionally, 150 controls of the same age and gender were also recruited. Serum vitamin D and fasting insulin levels were estimated by the electrochemiluminescence immunoassay (ECLIA) method. And, high-performance liquid chromatography (HPLC) was used to analyze HbA1c. Pearson’s correlation coefficient was used to determine the association of vitamin D with HbA1c and HOMA-IR.

Results: About 71% of diabetes patients had low vitamin D levels, compared to 31% in the control group. Vitamin D-deficient T2DM subjects had significantly higher HOMA-IR and HbA1c levels. In addition, a strong negative association between vitamin D and HOMA-IR (r = -0.75) and vitamin D and HbA1c (r = -0.73) has been demonstrated among T2DM patients.

Conclusions: Vitamin D deficiency is correlated with ineffective glycemic control, and the reason might be its potential role in the secretion and sensitivity of insulin. Therefore, vitamin D screening must be incorporated as a routine check-up for T2DM patients.

Downloads

Download data is not yet available.

References

American Diabetes Association “Diagnosis and classification of diabetes mellitus”. Diabetes Care 31(Suppl 1) (2011), S62–S69. DOI: 10.2337/dc10-S062.

A Aregbesola et al. “Gender difference in type 2 diabetes and the role of body iron stores”. Ann Clin Biochem 54(1) (2017), pp. 113–120. DOI: 10.1177/0004563216646397.

A G Pittas et al. “The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis”. J Clin Endocrinol Metab 92(6) (2007), pp. 2017–2029. DOI: 10.1210/jc.2007-0298.

A M Borissova et al. “The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients”. Int J Clin Pract 57(4) (2003), pp. 258–261. DOI: 12800453.

A W Norman et al. “Vitamin D deficiency inhibits pancreatic secretion of insulin”. Science 209(4458) (1980), pp. 823–825. DOI: 10.1126/science.6250216.

B Maestro et al. “Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells”. Endocr J 47(4) (2000), pp. 383–391. DOI: 10.1507/endocrj.47.383.

B Singh and A Saxena. “Surrogate markers of insulin resistance: A review”. World J Diabetes 1(2) (2010), pp. 36–47. DOI: 10.4239/wjd.v1.i2.36.

B Thorand et al. “Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: results from the MONICA/KORA Augsburg study”. Diabetes Care 34(10) (2011), pp. 2320–2322. DOI: 10.2337/dc11-0775.

C A Peterson, A K Tosh, and A M Belenchia. “Vitamin D insufficiency and insulin resistance in obese adolescents”. Ther Adv Endocrinol Metab 5(6) (2014), pp. 166–189. DOI: 10.1177/2042018814547205.

D D Bikle. “Vitamin D metabolism, mechanism of action, and clinical applications”. Chem Biol 21(3) (2014), pp. 319–329. DOI: 10.1016/j.chembiol.2013.12.016.

D R Matthews et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man”. Diabetologia 28(7) (1985), pp. 412–419. DOI: 10.1007/BF00280883.

E Bonora et al. “Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity”. Diabetes Care 23(1) (2000), pp. 57–63. DOI: 10.2337/diacare.23.1.57.

G S Hotamisligil et al. “Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance”. J Clin Invest 95(5) (1995), pp. 2409–2415. DOI: 10.1172/JCI117936.

I Kostoglou-Athanassiou et al. “Vitamin D and glycemic control in diabetes mellitus type 2”. Ther Adv Endocrinol Metab 4(4) (2013), pp. 122–128. DOI: 10.1177/2042018813501189.

J A Alvarez and A Ashraf. “Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis”. Int J Endocrinol (2010), pp. 351385–351385. DOI: 10.1155/2010/351385.

K C Chiu et al. “Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction”. Am J Clin Nutr 79(5) (2004), pp. 820–825. DOI: 10.1093/ajcn/79.5.820.

M A Bayani et al. “Status of vitamin-D in diabetic patients”. Caspian J Intern Med 5(1) (2014), pp. 40–42.

M Blum et al. “Vitamin D(3) in fat tissue”. Endocrine 33(1) (2008), pp. 90–94. DOI: 10.1007/s12020-008-9051-4.

M F Holick. “Vitamin D status: measurement, interpretation, and clinical application”. Ann Epidemiol 19(2) (2009), pp. 73–78. DOI: 10.1016/j.annepidem.2007.12.001.

M S Hutchinson et al. “Serum 25-hydroxyvitamin D levels are inversely associated with glycated haemoglobin (HbA1c). The Tromso Study”. Scand J Clin Lab Invest 71(5) (2011), pp. 399–406. DOI: 10.3109/00365513.2011.575235.

P Lemieux et al. “Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial”. Eur J Endocrinol 181(3) (2019), pp. 287–299. DOI: 10.1530/EJE-19-0156.

S Ghavam et al. “Evaluation of HbA1C and serum levels of vitamin D in diabetic patients”. J Family Med Prim Care 7(6) (2018), pp. 1314–1318. DOI: 10.4103/jfmpc.jfmpc_73_18.

S I Sherwani et al. “Significance of HbA1c test in diagnosis and prognosis of diabetic patients”. Biomark Insights 11 (2016), pp. 95–104. DOI: 10.4137/BMI.S38440.

S Kumar et al. “Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D”. Postgrad Med J 70(824) (1994), pp. 440–443. DOI: 10.1136/pgmj.70.824.440.

X Palomer et al. “Role of vitamin D in the pathogenesis of type 2 diabetes mellitus”. Diabetes Obes Metab 10(3) (2008), pp. 185–197. DOI: 10.1111/j.1463-1326.2007.00710.x.

Y Gao et al. “The relationship between serum 25-hydroxy vitamin D and insulin sensitivity and β-cell function in newly diagnosed type 2 diabetes”. J Diabetes Res (2015), pp. 636891–636891. DOI: 10.1155/2015/636891.

Y Singh et al. “A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents”. J Clin Res Pediatr Endocrinol 5(4) (2013), pp. 245–251. DOI: 10.4274/Jcrpe.1127.

Yousefi Rad et al. “The effects of vitamin D supplementation on glucose control and insulin resistance in patients with diabetes type 2: A randomized clinical trial study”. Iran J Public Health 43(12) (2014), pp. 1651–1656.

GA-153-2022

Published

08-11-2022

How to Cite

Narayanan, S.-K., & Gopikuttan, R. (2022). The correlation of vitamin D with HOMA-IR and glycated hemoglobin in type 2 diabetes mellitus patients. Baghdad Journal of Biochemistry and Applied Biological Sciences, 3(04), 273–285. https://doi.org/10.47419/bjbabs.v3i04.153

Plaudit